Axcelis Wins The 2024 SK hynix CSO Safety and Health Award

2025-02-06 IDOPRESS

Award Recognizes Companies Who Achieve Highest Level of Safety

BEVERLY,Mass.,Feb. 3,2025 --Axcelis Technologies,Inc. (Nasdaq: ACLS),a leading supplier of enabling ion implantation solutions for the semiconductor industry,has received the '2024 SK hynix CSO Safety and Health Award'. This prestigious award honors companies whose dedication and commitment in supplying products and services meet SK hynix's high standards for fab site and personal safety. The award was presented by Kim Youngsik,Chief Production Officer (CPO) of SK hynix,at a ceremony held at the SK hynix SUPEX Center in Icheon,Korea. Recipients are a select group of suppliers chosen for their exemplary performance in the areas of: Compliance with Regulations,Compliance with SK hynix policies,Improvements in the Company's EHS performance,and Reducing Overall Risks in the Semiconductor Supply Chain.

"It is an honor for Axcelis to receive the 2024 SK hynix CSO Safety and Health Award from SK hynix," said Russell Low,Axcelis' President and Chief Executive Officer. "This award is a testament to our dedication to customer collaboration and satisfaction,and our unwavering commitment to environmental sustainability and health and safety.

Vice President Kim Youngsik,commented,"Axcelis' exceptional commitment to health and safety has set them apart and is foundational to helping us achieve our priorities and serve our customers."

About Axcelis:


Axcelis (Nasdaq: ACLS),headquartered in Beverly,has been providing innovative,high-productivity solutions for the semiconductor industry for over 45 years. Axcelis is dedicated to developing enabling process applications through the design,manufacture and complete life cycle support of ion implantation systems,one of the most critical and enabling steps in the IC manufacturing process. Learn more about Axcelis at www.axcelis.com.

CONTACTS:

Press/Media Relations Contact:


Maureen Hart


Senior Director,Corporate & Marketing Communications


Telephone: (978) 787-4266


Email: Maureen.Hart@axcelis.com

Axcelis Investor Relations Contact:


David Ryzhik


Senior Vice President,Investor Relations and Corporate Strategy


Telephone: (978) 787-2352


Email: David.Ryzhik@axcelis.com

Logo - /up/2025/0206/25020620014394205659.jpg

Disclaimer: This article is reproduced from other media. The purpose of reprinting is to convey more information. It does not mean that this website agrees with its views and is responsible for its authenticity, and does not bear any legal responsibility. All resources on this site are collected on the Internet. The purpose of sharing is for everyone's learning and reference only. If there is copyright or intellectual property infringement, please leave us a message.

Newest

1Cangxi County Holds 2026 New Year's Cultural Performance for the Public

Cangxi County Holds 2026 New Year's Cultural Performance for the Public

2The First Series of the World Chinese Medicine Forum in 2025 Concludes Successfully

The First Series of the World Chinese Medicine Forum in 2025 Concludes Successfully

3The Second Series of the World Chinese Medicine Forum in 2025 Concludes Successfully

The Second Series of the World Chinese Medicine Forum in 2025 Concludes Successfully

4Tianjiang Pharmaceutical, a Subsidiary of China TCM, and Singapore College of Traditional Chinese Medicine Sign Strategic Cooperation Framework Agreement on TCM Education and Exchange

Tianjiang Pharmaceutical, a Subsidiary of China TCM, and Singapore College of Traditional Chinese Medicine Sign Strategic Cooperation Framework Agreement on TCM Education and Exchange

5Tianjiang Pharmaceutical, a Subsidiary of China TCM, Participates in the 4th CACM Specialized Disease Collaboration Platform Annual Conference & 10th Jiangsu Traditional Chinese Medicine Academic Conference

Tianjiang Pharmaceutical, a Subsidiary of China TCM, Participates in the 4th CACM Specialized Disease Collaboration Platform Annual Conference & 10th Jiangsu Traditional Chinese Medicine Academic Conference

6Tianjiang Pharmaceutical, a Subsidiary of China TCM, and Federation of Chinese Medicine & Acupuncture Societies of Australia Sign Strategic Cooperation Framework Agreement

Tianjiang Pharmaceutical, a Subsidiary of China TCM, and Federation of Chinese Medicine & Acupuncture Societies of Australia Sign Strategic Cooperation Framework Agreement

©copyright 2009-2020 Singapore Info Map